Keytruda gets NICE endorsement for Cancer Drugs Fund

27 April 2018

The UK's National Institute for Care and Health Excellence (NICE) has issued confirmation today that it recommends the use of Keytruda (pembrolizumab) within the Cancer Drugs Fund (CDF) for untreated locally advanced or metastatic urothelial carcinoma in adults, where chemotherapy is unavailable.

Keytruda is already the only immunotherapy that has been recommended by the NICE for inclusion in the CDF for urothelial cancer patients who have failed on platinum-containing chemotherapy. This latest decision follows new evidence showing the efficacy of the drug in treating a variety of cancers.

Urothelial cancer is the most common form of bladder cancer and accounts for more than 90% of cases. Bladder cancer is the seventh most common cancer in the UK and the fourth most common in men, yet it remains an underfunded area of research, with half of patients diagnosed going on to die from the disease.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK